Tvardi Therapeutics, Inc. Common Stock (TVRD) Stock Price

TVRDStock

$1.82−93.65%52W

Market Cap$24.28M

P/E—

PEG Ratio—

Div yield—

Beta0.36

TVRD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-61.80%

Price vs S&P 500 (4W)-30.10%

VGM Score38.54

Book Value / Share (Quarterly)$1.55

P/TBV (Annual)1.96x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-32.30%

Cash Flow / Share (Quarterly)$-2.63

Price vs S&P 500 (YTD)-70.56%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-700.06%

EPS (TTM)$-1.60

10-Day Avg Trading Volume0.16M

EPS Excl Extra (TTM)$-1.60

Revenue Growth (5Y)-18.54%

EPS (Annual)$-46.60

ROI (Annual)-125.86%

Gross Margin (Annual)91.31%

Net Profit Margin (5Y Avg)-428.07%

Cash / Share (Quarterly)$2.66

Revenue Growth QoQ (YoY)20.33%

ROA (Last FY)-201.33%

Revenue Growth TTM (YoY)-78.98%

EBITD / Share (TTM)$-3.20

ROE (5Y Avg)-70.79%

Operating Margin (TTM)-594.97%

Cash Flow / Share (Annual)$-2.50

P/B Ratio1.14x

P/B Ratio (Quarterly)2.06x

Net Income / Employee (Annual)$-5,905,600

Net Interest Coverage (TTM)-0.05x

ROA (TTM)-43.90%

EPS Incl Extra (Annual)$-46.60

Current Ratio (Annual)2.86x

Quick Ratio (Quarterly)2.22x

3-Month Avg Trading Volume1.64M

52-Week Price Return-93.65%

Revenue / Employee (TTM)$296,700

Tangible BV / Share (Quarterly)$1.51

P/S Ratio (Annual)2.33x

Asset Turnover (Annual)0.20x

52-Week High$43.65

Operating Margin (5Y Avg)-418.22%

EPS Excl Extra (Annual)$-46.60

CapEx CAGR (5Y)120.65%

26-Week Price Return-50.56%

Quick Ratio (Annual)2.79x

13-Week Price Return-50.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.25x

Enterprise Value$-3.25M

Revenue / Share Growth (5Y)58.71%

Asset Turnover (TTM)0.06x

Revenue / Employee (Annual)$594,800

Inventory Turnover (Annual)0.33x

Pretax Margin (Annual)-998.53%

Cash / Share (Annual)$3.28

3-Month Return Std Dev203.93%

Net Income / Employee (TTM)$-1,286,600

ROE (Last FY)-207.61%

Net Interest Coverage (Annual)0.60x

EPS Basic Excl Extra (Annual)$-46.60

P/FCF (TTM)0.56x

Receivables Turnover (TTM)2.42x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.60

ROI (TTM)-64.17%

P/S Ratio (TTM)4.66x

Pretax Margin (5Y Avg)-429.29%

Revenue / Share (Annual)$4.69

Tangible BV / Share (Annual)$2.20

Price vs S&P 500 (52W)-111.96%

Year-to-Date Return-58.60%

5-Day Price Return-6.32%

EPS Normalized (Annual)$-46.60

ROA (5Y Avg)-75.02%

Net Profit Margin (Annual)-992.95%

Month-to-Date Return-15.24%

EBITD / Share (Annual)$-43.02

Operating Margin (Annual)-919.43%

LT Debt / Equity (Annual)0.65x

ROI (5Y Avg)-54.44%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.60

P/TBV (Quarterly)2.10x

P/B Ratio (Annual)1.93x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-700.06%

Book Value / Share (Annual)$2.23

Price vs S&P 500 (13W)-53.21%

Beta0.36x

P/FCF (Annual)5.89x

Revenue / Share (TTM)$2.34

ROE (TTM)-64.17%

52-Week Low$1.50

vGradeB

gGradeD

mGradeF

vgmGradeD

TVRD Earnings Surprise History

Q2 250.51est. -0.39

Q3 25-0.59est. -0.96

Q4 25-0.78est. -0.57

Q2 26-0.69est. -0.63

TVRD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.86

3.87

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
TVRDTvardi Therapeutics, Inc. Common Stock	B	D	F	$1.82
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Tvardi Therapeutics, Inc. Common Stock

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies that target STAT3 for fibrosis-driven diseases. Its lead candidate, TTI-101, is in Phase 2 development for idiopathic pulmonary fibrosis and hepatocellular carcinoma. The company also has a second product candidate, TTI-109, designed to enhance STAT3 targeting.